News

AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial
AAVB-039 delivers the full-length ABCA4 -protein, addressing the root cause of the disease and enabling treatment of all patients, independent of mutationCELESTE is informed by the STELLA prospective ...
'Crazy stuff': AC/DC help Wallabies power up
Wallabies lock Jeremy Williams is bracing for the hostility and volume, particularly at line-out time when clear ...